GlassScriptPhysician profile
Heather P Sullivan
NPI 1396918827
$31,987.93
in general payments reported to CMS, 2019-2025
18 companies · $68.39 in 2025
The $68.39 reported for 2025 was less than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $4,947 · 2023: $15K · 2024: $12K · 2025: $68.39.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $14K · Food and Beverage: $6,429 · Consulting Fee: $3,350 · Travel and Lodging: $2,783 · Education: $79.25.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $14,400.00 |
| Food and Beverage | $6,428.78 |
| Consulting Fee | $3,349.50 |
| Travel and Lodging | $2,783.03 |
| Education | $79.25 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $12,840.94 | 2022-2024 | Omvoh |
| Abbvie INC. | $6,561.88 | 2022-2025 | |
| E.R. Squibb & Sons, L.L.C. | $5,687.69 | 2023-2024 | Zeposia |
| Janssen Scientific Affairs, LLC | $1,769.72 | 2022-2023 | Stelara, Tremfya |
| Celgene Corporation | $1,589.71 | 2022-2024 | Zeposia |
| Pfizer INC. | $1,318.39 | 2022-2024 | |
| Janssen Biotech, INC. | $931.59 | 2022-2024 | Stelara |
| Daiichi Sankyo INC. | $526.76 | 2022-2024 | Injectafer |
| Takeda Pharmaceuticals U.S.A., INC. | $125.40 | 2022-2025 | Entyvio, Gattex |
| Boehringer Ingelheim Pharmaceuticals, INC. | $122.80 | 2023-2024 | Cyltezo |
| Organon LLC | $113.03 | 2023-2024 | Hadlima |
| Fresenius Kabi USA, LLC | $98.05 | 2023-2024 | Idacio |
| Pharmacosmos Therapeutics INC. | $93.18 | 2022-2023 | Monoferric |
| Celltrion USA INC. | $79.25 | 2023-2024 | Zymfentra, Yuflyma |
| Ferring Pharmaceuticals INC. | $72.63 | 2023-2024 | Rebyota |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $20.74 | 2022 | |
| Alcresta Therapeutics, INC. | $19.70 | 2023 | Relizorb |
| Braintree Laboratories, INC. | $16.47 | 2024 | Suflave, Sutab |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Heather Sullivan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.